...It lashed on the drug discovery service operations of Discovery Partners International Inc. and the Proskelia...
...the clinic, a selective androgen receptor modulator (SARM) to treat cachexia, was obtained through the ProSkelia...
...in 2010 NA Platform: drug delivery Duodopa levodopa/carbidopa [Uppsala University] 2009 Duodopa sales: €59M ($84.9M) ProSkelia...

...a $1 million milestone payment from NVS under a September deal between the pharma and ProSkelia...

...Europe's As & Bs Company Date Round Raised Biovitrum 8/1/01 Series A €96.7 Proskelia (A) 7/9/02...

...Mechelen, Belgium) took a major step toward clinical development. The company said it would acquire ProSkelia...
...2006 with about E51 million ($66.8 million) in cash (see B30). GLPG will get four ProSkelia...
...optimization, and the company hopes to announce a preclinical RA candidate in 2007. Under the ProSkelia...

...GLPG agreed to acquire PSK's ProSkelia French drug discovery subsidiary for E12.5 million ($16.4 million) in...
...PSK is eligible for E14.5 million ($19.1 million) in additional payments. GLPG also would assume ProSkelia's...
...has the right of first refusal on the cachexia program and also retains two other ProSkelia...

...Fortis; and Whitaker Securities were joint lead managers. GLPG also said it agreed to acquire ProSkelia...
...is eligible for EUR 14.5 million ($19.1 million) in additional payments. GLPG also would assume ProSkelia's...
...has the right of first refusal on the cachexia program and also retains two other ProSkelia...

...and commercialization. PSK retains rights to small molecules against the target. The target came from ProSkelia...

...it was coming from. The company was created by the merger of French musculoskeletal play Proskelia...

...When French drug discovery play ProSkelia SA and U.K. specialty pharma Strakan Group Ltd. merged last...

...public mid-year (see BioCentury, Dec. 6, 2004). The company, formed by the merger of France's ProSkelia...